Fig. 1 · Structure

Documents & Downloads

Cobicistat (GS-9350)

Cat. No. A11277 CAS 1004316-88-4

CYP3A Inhibitor

Cobicistat is a potent inhibitor of cytochrome P450 3A enzymes, including the important CYP3A4 subtype. It also inhibits intestinal transport proteins, increasing the overall absorption of several HIV medications, including atazanavir, darunavir and tenofovir alafenamide fumarate.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
CYP3A 30 nM-285 nM

Cobicistat (GS-9350) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Cobicistat (GS-9350) from 2 published references. In vitro models include stably transfected Chinese hamster ovary cells; Vero E6 cells.

Cobicistat (GS-9350) In Vitro Studies

In stably transfected Chinese hamster ovary cells, Cobicistat yielded an IC50 of 1.87±0.22 μmol/l for MATE1 transport of tetraethylammonium (3.6 μmol/l). In the same cell model, the IC50 for OCT2 transport of tetraethylammonium (3.6 μmol/l) was 24.0±4.6 μmol/l. In SARS-CoV-2-infected Vero E6 cells, Cobicistat treatment at 2.5 μM, 5 μM, or 10 μM decreased replication-competent virus in the supernatant, with a DMSO-only mixture used as the control. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cobicistat effects on MATE1 transport in transfected ovary cells

Cell-based study · stably transfected Chinese hamster ovary cells (OCT2 and MATE1) [1]

Model substrate inhibition studies were conducted in stably transfected Chinese hamster ovary cells (OCT2 and MATE1). Cobicistat most potently inhibited MATE1; IC50 = 1.87±0.22 μmol/l. Inhibition by compounds was studied by threefold serial dilution up to 100 μmol/l (cobicistat and dolutegravir).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MATE1IC50 MATE1 transport of tetraethylammonium (3.6 μmol/l): IC50 = 1.87±0.22 μmol/l[1]

Literature-Reported Treatment Conditions

Treatment concentration
threefold serial dilution up to 100 μmol/l
Reported limits
Not stated in the sentences used: route, schedule, vehicle, control.
Methods and source locations

Compound reported in the paper: Cobicistat

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Transporter inhibition assays (S42, S43); Table 2 legend (S76); Table 2 (T2.h1, T2.r1, T2.r4)

MATE1: MATE1 — Materials and methods > Transporter inhibition assays (S43); Table 2 legend (S76); Table 2 (T2.h1, T2.r1, T2.r4)

Cobicistat effects on OCT2 transport in transfected ovary cells

Cell-based study · stably transfected Chinese hamster ovary cells (OCT2 and MATE1) [1]

Model substrate inhibition studies were conducted in stably transfected Chinese hamster ovary cells (OCT2 and MATE1). Cobicistat showed weak inhibition of OCT2; IC50 = 24.0±4.6 μmol/l. Inhibition by compounds was studied by threefold serial dilution up to 100 μmol/l (cobicistat and dolutegravir).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
OCT2IC50 OCT2 transport of tetraethylammonium (3.6 μmol/l): IC50 = 24.0±4.6 μmol/l[1]

Literature-Reported Treatment Conditions

Treatment concentration
threefold serial dilution up to 100 μmol/l
Reported limits
Not stated in the sentences used: route, schedule, vehicle, control.
Methods and source locations

Compound reported in the paper: Cobicistat

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Transporter inhibition assays (S42, S43); Table 2 legend (S76); Table 2 (T2.h1, T2.r1, T2.r4)

OCT2: OCT2 — Materials and methods > Transporter inhibition assays (S43); Table 2 legend (S76); Table 2 (T2.h1, T2.r1, T2.r4)

Cobicistat effects on replication-competent virus in cell supernatants

Cell-based study · Vero E6 cells [2]

SARS-CoV-2-infected Vero E6 cells were treated with Cobicistat at 2.5 μM, 5 μM, or 10 μM. Cobicistat decreased replication-competent virus in supernatants collected at 24 h postinfection, with a DMSO-only mixture used as the control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
plaques were manually counted after dryingReported result Vero E6 cells infected at an 0.05 MOI; cobicistat was added at a concentration of 2.5, 5, or 10 μM in DMSO two hours postinfection; supernatants were collected at 24 h postinfection. Cobicistat was also able to decrease the levels of replication-competent virus in the supernatant of Vero E6 cells.[2]

Literature-Reported Treatment Conditions

Treatment concentration
2.5 μM, 5 μM, or 10 μM
Exposure duration
Two hours postinfection; Supernatants were collected at 24 h postinfection
Method
cobicistat was added
Vehicle
DMSO
Co-treatment
Other interventions in this design: SARS-CoV-2 0.05 MOI. Compound effect isolated by the comparison: A 10 μM DMSO-only mixture was used as a control.
Methods and source locations

Compound reported in the paper: Cobicistat

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > In silico and in vitro analyses identify cobicistat as a candidate inhibitor of SARS-CoV-2 replication. (S13); MATERIALS AND METHODS > Animal experiments. (S147); MATERIALS AND METHODS > Effect of cobicistat on replication-competent virus. (S156, S157, S158, S159, S163); MATERIALS AND METHODS > Syncytium formation assay. (S200)

plaques were manually counted after drying: plaques were manually counted after drying; comparator: A 10 μM DMSO-only mixture — RESULTS > In silico and in vitro analyses identify cobicistat as a candidate inhibitor of SARS-CoV-2 replication. (S13); MATERIALS AND METHODS > Effect of cobicistat on replication-competent virus. (S156, S157, S159, S163)

Cobicistat (GS-9350) In Vivo Studies

SARS-CoV-2-infected Syrian hamsters received oral Cobicistat at 50 mg/kg daily beginning on the day of infection. Compared with placebo, Cobicistat administration significantly decreased infectious progeny in the lung when cumulative treatment effects were compared across the sampling days. [2]

Cobicistat effects on infectious viral progeny in hamster lungs

Animal study · Syrian hamsters (Mesocricetus auratus); Male and female hamsters at 6 to 10 weeks of age; n = 6 per group [2]

SARS-CoV-2-infected Syrian hamsters received oral Cobicistat at 50 mg/kg daily beginning on the day of infection. Compared with placebo, Cobicistat administration significantly decreased infectious progeny in the lung when cumulative treatment effects were compared across the sampling days.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Replication-competent viral titers as PFU on Vero E6 cellsReported result cobicistat (50 mg/kg daily): cobicistat administration resulted in a significant decrease in the amount of infectious progeny in the lung; comparing the cumulative effects of treatments at both day 3 and day 5 p.i.[2]

Conditions shared by the study groups

Route
orally
Treatment course
Beginning on the day of infection; once a day. On days 3 and 5 following infection, three randomly assigned animals per group were terminated to prepare samples for downstream analyses.
Vehicle
10% dimethyl sulfoxide (DMSO), 40% corn oil, and 50% strawberry syrup
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Cobicistat 50 mg/kgplacebocobicistat (50 mg/kg daily): cobicistat administration resulted in a significant decrease in the amount of infectious progeny in the lung; comparing the cumulative effects of treatments at both day 3 and day 5 p.i.[2]
Cobicistat 50 mg/kg
Model: Syrian hamsters (Mesocricetus auratus); Male and female hamsters at 6 to 10 weeks of age; n = 6 per group
Methods and source locations

Compound reported in the paper: Cobicistat

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > The combination of cobicistat and remdesivir decreases viral replication and disease progression in infected Syrian hamsters. (S71, S74); MATERIALS AND METHODS > Animal experiments. (S142, S145, S146, S147, S148); MATERIALS AND METHODS > Effect of cobicistat on replication-competent virus. (S166); FIG 6 legend (S311, S312)

Replication-competent viral titers as PFU on Vero E6 cells: Replication-competent viral titers as PFU on Vero E6 cells; comparator: placebo — RESULTS > The combination of cobicistat and remdesivir decreases viral replication and disease progression in infected Syrian hamsters. (S71, S74); FIG 6 legend (S311, S312)

Cobicistat 50 mg/kg · RESULTS > The combination of cobicistat and remdesivir decreases viral replication and disease progression in infected Syrian hamsters. (S71, S74); MATERIALS AND METHODS > Animal experiments. (S146, S147, S148); FIG 6 legend (S312)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1004316-88-4
Applications CYP3A Inhibitor
Formula C40H53N7O5S2
Molecular Weight 766
Synonyms GS9350
SMILES
CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 85 mg/mL (109.53 mM)
Water Insoluble
Ethanol 85 mg/mL (109.53 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
5% DMSO+40% PEG 300+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Cobicistat (GS-9350) Research References

  1. [1] Lepist EI, Zhang X, Hao J, et al. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. Kidney Int (2014). PMID: 24646860 DOI: 10.1038/ki.2014.66 Source material
  2. [2] Shytaj IL, Fares M, Gallucci L, et al. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters. mBio (2022). PMID: 35229634 DOI: 10.1128/mbio.03705-21 Source material

Added to your cart

View Cart Checkout
Loading...